This article is more than 5 years old. Information may no longer be current.
PDT monotherapy effective in eyes with polypoidal choroidal vasculopathy
Reduced-fluence photodynamic therapy monotherapy maintained or improved visual acuity in polypoidal choroidal vasculopathy patients for 24 months, according to a study.
The prospective interventional case series included 38 eyes of 38 patients who underwent PDT with a reduced laser fluence of 25 J/cm2 using the Visulas PDT system 690s (Carl Zeiss Meditec). Patients had no prior therapy for polypoidal choroidal vasculopathy and underwent a mean of 1.9 treatments over 24 months.
Mean logMAR best corrected visual acuity improved from 0.43 at baseline to 0.28 at 12 months (P < .0001) and 0.29 at 24 months (P = .001).
Thirteen eyes with a visual acuity better than 20/40 at baseline showed significant improvement of mean logMAR BCVA at 1 year, with visual acuities maintained at 2 years.
Subretinal hemorrhages occurred in five eyes; however, they naturally resolved within 6 months, and no eyes lost more than three lines of vision.
LogMAR BCVA was improved by more than three lines or maintained in 36 eyes at 2 years.